Drugs and Pharmaceuticals News - Page 2

Page 2 of Drugs and Pharmaceuticals News issued by the Send2Press® Newswire service.



C Diff Foundation Presents Award to CutisPharma in Recognition of Contribution to C. diff. Community

NEW PORT RICHEY, Fla., March 16, 2018 (SEND2PRESS NEWSWIRE) — The C Diff Foundation announced today that it presented CutisPharma, Inc., its “Making a Difference” award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for C.diff. patients.

Delta Care Rx Now Integrates with Suncoast Electronic Medical Records

PITTSBURGH, Pa., Feb. 16, 2018 (SEND2PRESS NEWSWIRE) — Delta Care Rx, a leading pharmaceutical innovator in end of life care, announces a robust integration with Suncoast by Complia Health, a leading global provider of home health care and hospice software solutions.

ScriptDrop and Albertsons Hurricane Relief Efforts To Be Covered on ‘The Success Files’ hosted by Rob Lowe

COLUMBUS, Ohio, Nov. 2, 2017 (SEND2PRESS NEWSWIRE) — ScriptDrop, a healthcare technology company providing medication reminders and deliveries while fighting prescription abandonment and abuse, today announced that it will be featured on the educational series “Success Files” hosted by Rob Lowe, distributed to Public Television and PBS Member Stations in 2018. (*UPDATED*)

Paragon BioTeck Calls Emerging Leaders to Apply for 2018 Ophthalmology Scholarship

PORTLAND, Ore., Oct. 2, 2017 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately-held pharmaceutical and medical device company, today announced the call for the next Koch Kellan Scholar. The annual Koch Kellan Scholarship honors one outstanding graduate medical student committed to elevating the standard of eye care through social responsibility and a clinical, teaching, or research career in ophthalmology. A Paragon Gives initiative, the scholarship reinforces the fundamental mission of Paragon BioTeck to drive innovations to address unmet and underserved medical needs.

Edmond Hooker, MD, Darrel Hicks, and Bruce Rippe Discuss Medical Mattress Contamination Issues on C.diff Spores and More, Aug. 1

TAMPA, Fla., July 31, 2017 (SEND2PRESS NEWSWIRE) — C Diff Foundation’s, “C. diff. Spores and More Global Broadcasting Network,” is honored to announce Dr. Edmond Hooker, MD – Associate Professor of Health Services Administration at Xavier University, Darrel Hicks, a well-known hospital environment specialist and educator, and Bruce Rippe, CEO of Trinity Guardion, manufacturer of the Trinity Guardion Patient Protective Barrier, as our guest speakers on August 1, 2017.

ChemDiv Selected by Arcus Biosciences as the Sole Chemistry Provider for its Discovery Screening Collection

SAN DIEGO, Calif., June 12, 2017 (SEND2PRESS NEWSWIRE) — ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus’s growing HTS screening collection. This collaboration, which utilized Arcus’s medicinal chemistry knowledge and ChemDiv’s computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.

Verify Smart Corp Signs Letter of Intent to Acquire Equity Stake and Exclusive International Reseller Rights in Med-Con Technologies, LLC

FERNLEY, Nev., June 8, 2017 (SEND2PRESS NEWSWIRE) — Verify Smart Corporation (OTC:VSMR / OTCMKTS:VSMR) a Global innovator in financial fraud prevention and digital distribution solutions announced today that it has signed a Letter of Intent to acquire an equity stake and exclusive international reseller rights in Med-Con Technologies, LLC for cash and stock.

EPIC Insurance adds Reba Mathew, Pharm.D., R.Ph to Employee Benefits Consulting Pharmacy Practice

SAN FRANCISCO, Calif. and HOUSTON, Texas, May 16, 2017 (SEND2PRESS NEWSWIRE) — EPIC Insurance Brokers & Consultants, a retail property, casualty insurance brokerage and employee benefits consultant, announced today that Reba Mathew Pharm.D., R.Ph has joined the firm’s Employee Benefits Consulting Practice as Pharmacy Practice Director.

Medical Experts Unite Regarding Health Benefits of Testosterone Therapy in Women

IRVING, Texas, April 19, 2017 (SEND2PRESS NEWSWIRE) – BioTE(R) Medical announces a forum of medical experts gathering before the Age Management Medicine Group (AMMG) to form consensus on testosterone therapy in women. The AMMG conference runs April 27-30, 2017 in Orlando, Florida.

Delta Care Rx Announces Patrick White, MD, Inaugural Recipient of Delta Distinguished Scholar Award

PITTSBURGH, Pa., April 18, 2017 (SEND2PRESS NEWSWIRE) — Delta Care Rx today announced the first-ever recipient of the Delta Distinguished Scholar award. Patrick White, MD, HMDC, FACP, FAAHPM, chief medical officer of BJC Hospice, St. Louis, and assistant professor of medicine at Washington University, has received an initial $25,000 research grant, with a $500,000 lifetime potential, for study into the comparative and cost effectiveness of pharmaceuticals.

Trump’s wrong attack on Opioid Epidemic, says Dr. Harte

CORTE MADERA, Calif., March 31, 2017 (SEND2PRESS NEWSWIRE) — Dr. Don Harte, chiropractic activist, says Trump’s new panel, headed by Chris Christie, to deal with the opioid epidemic, is “philosophically and scientifically dead wrong.” Dr. Harte declares, “The reason for this epidemic is clear. Orthopedists and other doctors freely prescribe Oxycontin, Fentanyl, Soma and other opioid drugs, get their patients addicted.”

Ruling Affirms Patent Claim for Paragon BioTeck’s R-Phenylephrine Hydrochloride Formulation

PORTLAND, Ore., Nov. 21, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc. announces a monumental ruling handed down by the United States Patent and Trademark Office (USPTO) affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.

Join Brandy Vaughan of LearnTheRisk.org for Important and Free Talk ‘Is Your Health For $ale?’ in San Francisco

SAN FRANCISCO, Calif., Sept. 22, 2016 (SEND2PRESS NEWSWIRE) — Join Brandy Vaughan, former Merck pharmaceutical rep and founder of LearnTheRisk.org, a campaign of the Council for Vaccine Safety, for a FREE talk on Sunday, Sept. 25, 2016 at 1 p.m. in San Francisco, as she exposes the dark side of today’s ‘health’care system and explains how we can stay healthy in a system that wants to keep us sick.

Paragon BioTeck, Inc. Announces Call for 2017 Koch Kellan Scholarship Applicants

PORTLAND, Ore., Sept. 1, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today a call for applications for the 2017 Koch Kellan Scholarship, awarded annually to an outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology. A Paragon Gives initiative, the Koch Kellan Scholarship reinforces the fundamental mission of Paragon BioTeck to drive innovations to address unmet and underserved medical needs and improve the quality of lives around the world.

Pharma companies gain competitive advantage from 1 day Masterclass on Artificial Intelligence in Pharma sales and marketing

NEW YORK, N.Y., Aug. 2, 2016 (SEND2PRESS NEWSWIRE) — Eularis announces the release of their one-day Masterclass “Using Artificial Intelligence to Transform Sales and Revenue: What Pharma Need to Know.” Many Pharma sales and marketing teams do not understand the relevance, nor the critical importance, of AI to achieve stronger results in their roles, and believe it is not relevant to them or their job. This is an incorrect assumption.

BioTE Medical Poised to Change Healthcare as it Expands into Georgia

ATLANTA, Ga., May 11, 2016 (SEND2PRESS NEWSWIRE) — BioTE(R) Medical, a leader in bioidentical hormone replacement therapy (BHRT), is expanding its nationwide network of certified physicians into the Atlanta, Georgia market this month.

W&L Hopes Faster FDA Publication of Potential Risk Signals for SGLT2 Inhibitors: Newest – Stroke, Thromboembolic Events, Acute Kidney Injury

NEW YORK, N.Y., April 1, 2016 (SEND2PRESS NEWSWIRE) — Weitz and Luxenberg, P.C., said today it hopes potentially fatal side effects associated with SGLT2 inhibitor drugs will be reported to consumers faster, since people taking these next-generation diabetes medications deserve to be notified of the health dangers shortly after they have been reported to the U.S. Food and Drug Administration (FDA).

Paragon BioTeck Receives EN ISO 13485:2012 Certification

PORTLAND, Ore., March 29, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today that it has received EN ISO 13485:2012 certification, signifying the company’s successful implementation of an effective quality management system.

California Chiropractor calls new use for common diabetes drug ‘NUTS!’

CORTE MADERA, Calif., Feb. 22, 2016 (SEND2PRESS NEWSWIRE) — Dr. Don Harte, noted Marin County chiropractic activist, is calling the latest proposed use of the diabetes drug, metformin, ‘Nuts!’ ‘In the 2/22/16 issue of TIME magazine, in what they call the ‘Longevity Issue,’ I have seen THE most outrageous potential claim that Medicine has ever made,’ declares Dr. Harte.

Delta Care Rx Sponsors Innovative Hospice Nurse Intern Program of Four Seasons Compassion for Life

FLAT ROCK, N.C., Jan. 12, 2016 (SEND2PRESS NEWSWIRE) — A shared commitment to the greater good and a growing need for trained hospice professionals led Delta Care Rx, a nationally known hospice pharmaceutical provider, to partner with Four Seasons Compassion For Life in the recent development and implementation of an innovative 12-week ‘Hospice Nurse Internship Program.’

BioTE Medical Study Showing Promising Results for Military Veterans Diagnosed with PTSD and TBI

IRVING, Texas, Dec. 30, 2015 (SEND2PRESS NEWSWIRE) — A current BioTE(R) Medical Combat Trauma Treatment Study (in conjunction with the Veterans Advocacy Center (VAC)) is showing promising results in helping veterans suffering from Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI).

Weitz and Luxenberg Adds Serious Urinary Tract Infections to SGLT2 Inhibitor Injuries Probe

NEW YORK, N.Y., Dec. 7, 2015 (SEND2PRESS NEWSWIRE) — Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized after developing urosepsis (serious infection of the blood) or pyelonephritis (infection of the kidneys) from SGLT2 inhibitor-associated urinary tract infections.

Rally Demanding Vaccine Truth at Frank Ogawa Plaza in Solidarity with Rally at the CDC in Atlanta

OAKLAND, Calif., Oct. 19, 2015 (SEND2PRESS NEWSWIRE) — Council for Vaccine Safety, and A Voice for Choice, in collaboration with community leaders, announce that on October 24, 2015 at 12 noon, protesters will rally at Frank Ogawa Plaza in Oakland, Calif. in solidarity with the Truth, Transparency and Freedom Rally happening on the same day at the CDC in Atlanta, Georgia.

E-VAI – the Artificial Intelligence Platform from Eularis Changes the Rules of the Marketing in Pharma

NEW YORK, N.Y. and Tokyo, Sept. 15, 2015 (SEND2PRESS NEWSWIRE) — Eularis announces today the release of E-VAI, the latest development in sophisticated artificial intelligence technology delivering next generation analytics and decision making to Pharma marketers globally. E-VAI changes the game for marketers struggling to understand and get value from their marketing.

SAN FRANCISCO: SB277 Protest Rally and Health Freedom March

SAN FRANCISCO, Calif., July 3, 2015 (SEND2PRESS NEWSWIRE) — The Council for Vaccine Safety announced today that on Friday, July 3, Californians will rally simultaneously in cities across the state, to illuminate the truth and stand for health, safety, education, medical freedom and justice for all. Join us as we stand in sincere opposition to the unwarranted and threatening force of the government as it moves – in partnership with big pharma – to strip us of our parental, health and medical freedoms through proposed mandated healthcare legislation, such as California Senate Bill 277.

Zofran Birth Defect Cases Being Accepted by Weitz and Luxenberg

NEW YORK, N.Y., April 7, 2015 (SEND2PRESS NEWSWIRE) — Weitz and Luxenberg, P.C., announced it is accepting cases of congenital heart defects and cleft facial abnormalities in children whose mothers took the prescription drug Zofran during pregnancy to relieve symptoms of morning sickness.

Weitz & Luxenberg’s Relkin Appointed to Xarelto MDL Leadership Team

NEW YORK, N.Y., Feb. 11, 2015 (SEND2PRESS NEWSWIRE) — Ellen Relkin, of counsel attorney with Weitz and Luxenberg, P.C., has been named to the plaintiffs’ steering committee created by judicial order to facilitate lawsuits against the makers of the anticoagulant drug Xarelto, the personal injury and mass tort law firm today announced.

Paragon BioTeck to Exhibit at American Academy of Ophthalmology Annual Meeting in Chicago

PORTLAND, Ore., Oct. 15, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago, Ill., on October 18 – 21.

National Law Journal Names Weitz and Luxenberg to ‘Elite Trial Lawyers’ List, Reveals 2 Keys to Firm’s $9-Billion Actos Verdict

NEW YORK, N.Y., Oct. 1, 2014 (SEND2PRESS NEWSWIRE) — Two keys that earlier this year led to a $9-billion courtroom victory by Weitz and Luxenberg, P.C., against the maker of the diabetes drug Actos, were revealed Monday when National Law Journal named the New York City-based personal injury firm to its debut list of ‘America’s Elite Trial Lawyers.’

Paragon BioTeck announces FDA Approved Phenylephrine Hydrochloride Ophthalmic Solution Readily Available

PORTLAND, Ore., June 4, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held U.S. biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, announces its FDA approved Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil, is readily available through Bausch + Lomb or your primary wholesaler.

Weitz and Luxenberg – Jury Awards $9 Billion to Diabetic Put at Cancer Risk by Actos

NEW YORK CITY, N.Y., April 9, 2014 (SEND2PRESS NEWSWIRE) — A Louisiana jury has awarded $9 billion to a New York man who developed bladder cancer after taking Actos, Weitz and Luxenberg announced today. The verdict, issued Monday night, orders Takeda Pharmaceuticals to pay $6 billion in punitive damages, and Eli Lilly to pay $3 billion.

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent Readily Available

PORTLAND, Ore., April 9, 2014 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.

Paragon Puts Ilast® Center Stage

PORTLAND, Ore., Nov. 8, 2013 (SEND2PRESS NEWSWIRE) — Leading biopharmaceutical company Paragon BioTeck, Inc. announced today that it plans to launch its new line of products, known as Ilast(R), at the Annual American Academy of Ophthalmology meeting in New Orleans. Paragon signed an exclusive distribution agreement with Horus Pharma to supply Ilast(R) ocular care products in the U.S. last month, and the company is excited to release these products to ophthalmology professionals.

Paragon BioTeck Signs Exclusive Distribution Agreement with Horus Pharma for Ilast

PORTLAND, Ore., Oct. 9, 2013 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc. today announced that it has signed a distribution agreement with Horus Pharma for rights to supply the Ilast(R) range of its medical-grade ocular hygiene and lid care products within the United States; it begins on an exclusive basis this month.

Heart Imaging Technologies Wins $2.5M NIH Grant for Clinical Trials

DURHAM, N.C., Sept. 4, 2013 (SEND2PRESS NEWSWIRE) — HeartIT, the global leader that pioneered the first FDA approved zero-footprint medical imaging workstation, announced today that it has received a $2.5M grant from the NIH in order to develop the ‘Cloud Based Corelab of the Future.’

Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine

MADISON, N.J. and TIGARD, Ore., April 19, 2013 (SEND2PRESS NEWSWIRE) — Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.

Laboratory Supply Distributors Corp. Unveils New Product Catalog

MILLVILLE, N.J., Feb. 25, 2013 (SEND2PRESS NEWSWIRE) — Laboratory Supply Distributors Corp., a provider of diverse products for the chromatography, biotechnology, pharmaceutical and environmental industries, this week announced the launch of its 2013 catalog. It showcases many new products for the life science and biotechnology markets.

Eularis Updates Reports That Help Pharmaceutical Companies Do More for Real Growth Than Simply Downsizing

LONDON, U.K. (SEND2PRESS NEWSWIRE) — The pharmaceutical industry is facing unprecedented challenges on many fronts – a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results.

Pharmaceutical eMarketing using Social Media: How to Use It Effectively, Meet the Challenges (Regulatory and Others) and Measure Results in Dollar Terms

NEW YORK, N.Y. and LONDON, U.K. (SEND2PRESS NEWSWIRE) — Eularis is announcing the release of its report ‘How To Harness The Power Of Social Media In Pharmaceutical eMarketing.’ This report puts to rest the issues around ‘can’t,’ and shows Pharmaceutical marketers how they can utilize social media networks effectively to meet their marketing objectives.

Eularis to Address Marketing Return at Japanese Pharmaceutical Marketing Excellence Conference

TOKYO and LONDON, U.K., May 12 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, president of the New York and London-based pharmaceutical analytics company Eularis, will be delivering a presentation on how to tell if you are making the wrong marketing decision. The Pharmaceutical Marketing Excellence conference takes place in Tokyo, Japan.